General Pharmacological Principles

General pharmacological principles encompass the fundamental processes governing how drugs are discovered, developed, regulated, and administered to treat diseases. This comprehensive course covers drug development from initial discovery through clinical trials, FDA approval processes, drug classification systems, and the molecular mechanisms of drug-receptor interactions. Students explore various administration routes, regulatory frameworks established after historical tragedies like the thalidomide disaster, and factors affecting drug responses across different patient populations, providing essential knowledge for understanding modern therapeutic interventions with JoVE Coach.

• Understand the complete drug discovery pipeline from target identification to clinical candidate selection
• Explore preclinical development phases including animal testing for safety, toxicity, and pharmacokinetics
• Analyze the four phases of clinical trials and FDA approval processes for new medications
• Learn drug nomenclature systems including generic names, brand names, and USAN classifications
• Identify key regulatory milestones in US drug history including the 1938 Food, Drug, and Cosmetic Act
• Examine drug classification methods based on chemical structure and therapeutic applications
• Apply knowledge of drug-receptor binding mechanisms including covalent and non-covalent interactions
• Understand different administration routes and their impact on drug bioavailability and onset of action

1. Drug Discovery and Development Pipeline: The systematic process begins with target identification using biochemical assays and computational methods to identify molecular targets like receptors and enzymes. High-throughput screening of compound libraries identifies "hits" that bind to biological targets, which are then optimized through combinatorial chemistry to improve potency and reduce adverse effects. This process culminates in selecting drug candidates for clinical testing, with examples including the development of cholesterol-lowering statins from natural fungal compounds and the discovery of ACE inhibitors for hypertension treatment.

2. Clinical Trial Phases and FDA Approval: Clinical testing follows a structured four-phase approach mandated by US regulations. Phase I trials test 5-10 candidates on small groups to evaluate safety and pharmacokinetics. Phase II expands to 100-300 patients for efficacy assessment, while Phase III involves thousands of participants in double-blind studies across multiple centers. Phase IV represents post-marketing surveillance to identify rare adverse effects. The FDA's New Drug Application review process ensures safety and efficacy standards, with expedited pathways available for treatments addressing life-threatening conditions like cancer or rare diseases.

3. Drug Regulation and Historical Context: US drug regulation evolved through tragic events that shaped current safety standards. The 1937 Elixir Sulfanilamide tragedy, which killed over 100 people due to toxic diethylene glycol, led to the 1938 Food, Drug, and Cosmetic Act requiring safety testing. The thalidomide disaster prompted the 1962 Kefauver-Harris Amendments mandating efficacy proof alongside safety data. These regulations established the modern framework requiring Investigational New Drug (IND) applications and comprehensive risk-benefit analyses before human testing begins.

4. Drug Classification and Nomenclature Systems: Drugs receive multiple names throughout development and commercialization. The United States Adopted Names (USAN) program assigns nonproprietary generic names that become official when listed in the United States Pharmacopeia. Manufacturers create proprietary brand names for marketing, with single drugs potentially having multiple brand names from different companies. Classification systems organize drugs by chemical structure (like beta-lactam antibiotics) or therapeutic use (like antihypertensives), with controlled substances further categorized into DEA schedules based on abuse potential and medical utility.

5. Molecular Drug-Receptor Interactions: Drug efficacy depends on specific binding interactions with target receptors through various molecular forces. Covalent bonds, though strong and irreversible, are rare except in specialized applications like DNA-alkylating chemotherapy agents. Most therapeutic interactions involve weaker but more selective non-covalent forces including electrostatic interactions, hydrogen bonding, and hydrophobic effects. These selective binding mechanisms allow drugs to modify target cell activity without affecting other tissues, explaining why aspirin selectively inhibits COX enzymes while acetaminophen targets different pathways for pain relief.

6. Routes of Drug Administration: Drug delivery routes significantly impact therapeutic outcomes through differences in bioavailability, onset time, and duration of action. Enteral routes include oral administration (slowest onset due to GI absorption), sublingual delivery (rapid absorption bypassing liver metabolism), and rectal administration (useful when patients cannot swallow). Parenteral routes provide direct systemic access through intravenous injection (immediate effect), intramuscular injection (moderate absorption rate), or subcutaneous delivery (sustained release). Specialized routes like inhalation exploit the lung's large surface area for rapid absorption, while transdermal patches provide steady drug release over extended periods.